Summary Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes a range of hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neurological conditions. Its lead pipeline products include EG-1962, a proprietary formulation, which is used to treat aneurysmal subarachnoid hemorrhage, is in Phase 3 clinical trials and EG-1964 is in preclinical stage used to prevent recurrent chronic subdural hematoma. The company’s Precise, a proprietary, programmable, biodegradable polymer-based development platform develops products for the treatment of acute neurological conditions. Edge Therapeutics is headquartered in Berkeley Heights, New Jersey, the US. Edge Therapeutics Inc (EDGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the... Research Beam Model: Research Beam Product ID: 1916381 250 USD New
Edge Therapeutics Inc (EDGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Edge Therapeutics Inc (EDGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : July   2017
  • Pages : 37
  • Publisher : GlobalData
 
 
 
Summary

Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes a range of hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neurological conditions. Its lead pipeline products include EG-1962, a proprietary formulation, which is used to treat aneurysmal subarachnoid hemorrhage, is in Phase 3 clinical trials and EG-1964 is in preclinical stage used to prevent recurrent chronic subdural hematoma. The company’s Precise, a proprietary, programmable, biodegradable polymer-based development platform develops products for the treatment of acute neurological conditions. Edge Therapeutics is headquartered in Berkeley Heights, New Jersey, the US.

Edge Therapeutics Inc (EDGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 11
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 12
Edge Therapeutics Raises USD8 Million in Venture Financing 13
Edge Therapeutics Secures USD3 Million from Hercules Technology 13
Edge Therapeutics Raises US$18 Million In Series C Financing 14
Partnerships 15
Edge Therapeutics Enters into Agreement with Oakwood Labs 15
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 16
Equity Offering 17
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 17
Edge Therapeutics Raises USD92.5 Million in IPO 18
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 19
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 20
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 20
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 21
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 22
Debt Offering 22
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 22
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 23
Edge Therapeutics Inc - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
May 03, 2017: Edge Therapeutics Q1 net loss increases 27
May 03, 2017: Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress 28
Mar 02, 2017: Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 29
Nov 01, 2016: Edge Therapeutics Reports Third Quarter Financial Results 30
Aug 03, 2016: Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights 31
May 03, 2016: Edge Therapeutics Reports First Quarter 2016 Financial Results 32
Mar 08, 2016: Edge Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results 33
Corporate Communications 35
Feb 21, 2017: Edge Therapeutics appoints senior vice president of regulatory affairs 35
Oct 17, 2016: Edge Therapeutics Appoints Chief Operating Officer 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Edge Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 11
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 12
Edge Therapeutics Raises USD8 Million in Venture Financing 13
Edge Therapeutics Secures USD3 Million from Hercules Technology 13
Edge Therapeutics Raises US$18 Million In Series C Financing 14
Edge Therapeutics Enters into Agreement with Oakwood Labs 15
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 16
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 17
Edge Therapeutics Raises USD92.5 Million in IPO 18
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 19
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 20
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 20
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 21
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 22
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 22
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 23
Edge Therapeutics Inc, Key Competitors 24
Edge Therapeutics Inc, Key Employees 25List of Figures
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter